Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling.

Cimino PJ, Huang L, Du L, Wu Y, Bishop J, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Carew J, Nawrocki S, Jordan MA, Wilson L, Lloyd GK, Wirsching HG.

Biomed Rep. 2019 Apr;10(4):218-224. doi: 10.3892/br.2019.1196. Epub 2019 Mar 5.

2.

Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.

Ma M, Ding Z, Wang S, Ma L, Wang Y, Zhong L, Li Z, Yang J, Li W.

Bioorg Med Chem. 2019 May 1;27(9):1836-1844. doi: 10.1016/j.bmc.2019.03.035. Epub 2019 Mar 20.

PMID:
30910474
3.

In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.

Ma M, Zhao J, Cheng H, Deng M, Ding Z, Hou Y, Li F, Dou G, Li W.

Bioorg Med Chem. 2018 Sep 1;26(16):4687-4692. doi: 10.1016/j.bmc.2018.08.009. Epub 2018 Aug 4.

PMID:
30119994
4.

Design, synthesis and biological evaluation of anti-pancreatic cancer activity of plinabulin derivatives based on the co-crystal structure.

Fu Z, Hou Y, Ji C, Ma M, Tian Z, Deng M, Zhong L, Chu Y, Li W.

Bioorg Med Chem. 2018 May 1;26(8):2061-2072. doi: 10.1016/j.bmc.2018.03.005. Epub 2018 Mar 7.

PMID:
29571653
5.

Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.

Deng M, Li L, Zhao J, Yuan S, Li W.

Cancer Chemother Pharmacol. 2018 May;81(5):853-862. doi: 10.1007/s00280-018-3547-2. Epub 2018 Mar 12.

PMID:
29532153
6.

An Efficient Method for the Conjugation of Hydrophilic and Hydrophobic Components by Solid-Phase-Assisted Disulfide Ligation.

Muguruma K, Shirasaka T, Akiyama D, Fukumoto K, Taguchi A, Takayama K, Taniguchi A, Hayashi Y.

Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2170-2173. doi: 10.1002/anie.201712324. Epub 2018 Jan 19.

PMID:
29276821
7.

Click strategy using disodium salts of amino acids improves the water solubility of plinabulin and KPU-300.

Yakushiji F, Muguruma K, Hayashi Y, Shirasaka T, Kawamata R, Tanaka H, Yoshiwaka Y, Taguchi A, Takayama K, Hayashi Y.

Bioorg Med Chem. 2017 Jul 15;25(14):3623-3630. doi: 10.1016/j.bmc.2017.04.024. Epub 2017 May 4.

PMID:
28528081
8.

Synthesis of deuterium-enriched and fluorine-substituted plinabulin derivatives and evaluation of their antitumor activities.

Ding Z, Hou Y, Wang S, Sun T, Ma M, Guan H, Li W.

Mol Divers. 2017 Aug;21(3):577-583. doi: 10.1007/s11030-017-9742-y. Epub 2017 May 9.

PMID:
28488201
9.

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

Hardin C, Shum E, Singh AP, Perez-Soler R, Cheng H.

Expert Opin Pharmacother. 2017 May;18(7):701-716. doi: 10.1080/14656566.2017.1316374. Epub 2017 Apr 17. Review.

PMID:
28388240
10.

Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.

Ding Z, Cheng H, Wang S, Hou Y, Zhao J, Guan H, Li W.

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1416-1419. doi: 10.1016/j.bmcl.2017.01.096. Epub 2017 Feb 3.

PMID:
28228362
11.

[New natural products from the marine-derived Aspergillus fungi-A review].

Zhao C, Liu H, Zhu W.

Wei Sheng Wu Xue Bao. 2016 Mar 4;56(3):331-62. Review. Chinese.

PMID:
27382779
12.

Ferrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells.

Wieczorek A, Błauż A, Zakrzewski J, Rychlik B, Plażuk D.

ACS Med Chem Lett. 2016 Feb 22;7(6):612-7. doi: 10.1021/acsmedchemlett.6b00046. eCollection 2016 Jun 9.

13.

Novel Hybrid Compound of a Plinabulin Prodrug with an IgG Binding Peptide for Generating a Tumor Selective Noncovalent-Type Antibody-Drug Conjugate.

Muguruma K, Yakushiji F, Kawamata R, Akiyama D, Arima R, Shirasaka T, Kikkawa Y, Taguchi A, Takayama K, Fukuhara T, Watabe T, Ito Y, Hayashi Y.

Bioconjug Chem. 2016 Jul 20;27(7):1606-13. doi: 10.1021/acs.bioconjchem.6b00149. Epub 2016 Jul 7.

PMID:
27304609
14.

KPU-300, a Novel Benzophenone-Diketopiperazine-Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase.

Okuyama K, Kaida A, Hayashi Y, Hayashi Y, Harada K, Miura M.

PLoS One. 2015 Dec 30;10(12):e0145995. doi: 10.1371/journal.pone.0145995. eCollection 2015.

15.

Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.

Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, Lai Q, Yang Z, Chen Q, Yang J.

FEBS J. 2016 Jan;283(1):102-11. doi: 10.1111/febs.13555. Epub 2015 Nov 4.

16.

Phenotype-Guided Natural Products Discovery Using Cytological Profiling.

Ochoa JL, Bray WM, Lokey RS, Linington RG.

J Nat Prod. 2015 Sep 25;78(9):2242-8. doi: 10.1021/acs.jnatprod.5b00455. Epub 2015 Aug 21.

PMID:
26292657
17.

Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.

Ji YT, Liu YN, Liu ZP.

Curr Med Chem. 2015;22(11):1348-60. Review.

PMID:
25620094
18.

Development of a new benzophenone-diketopiperazine-type potent antimicrotubule agent possessing a 2-pyridine structure.

Hayashi Y, Takeno H, Chinen T, Muguruma K, Okuyama K, Taguchi A, Takayama K, Yakushiji F, Miura M, Usui T, Hayashi Y.

ACS Med Chem Lett. 2014 Jul 23;5(10):1094-8. doi: 10.1021/ml5001883. eCollection 2014 Oct 9.

19.

Medicinal chemistry and chemical biology of diketopiperazine-type antimicrotubule and vascular-disrupting agents.

Hayashi Y, Yamazaki-Nakamura Y, Yakushiji F.

Chem Pharm Bull (Tokyo). 2013;61(9):889-901.

20.

Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci).

Honda-Uezono A, Kaida A, Michi Y, Harada K, Hayashi Y, Hayashi Y, Miura M.

Biochem Biophys Res Commun. 2012 Nov 16;428(2):224-9. doi: 10.1016/j.bbrc.2012.10.014. Epub 2012 Oct 9.

PMID:
23063846

Supplemental Content

Loading ...
Support Center